Report Detail
Global Epilepsy Drugs Market Size, Status and Forecast 2019-2025
- RnM3402655 |
- 16 July, 2019 |
- Global |
- 104 Pages |
- QYResearch |
- Other
Epilepsy is characterized by recurrent seizures caused by the improper balance between inhibitory and excitatory signals in the brain. The symptoms of epilepsy, caused by brain malformations and tumors, birth trauma, and high-risk pregnancies, can be benign or life-threatening. A majority of epilepsy cases have an unknown etiology.
In terms of geography, the Americas led the global epilepsy drugs market and is likely to hold close to 50% of the revenue market shares. The growth of this market in the region is due to the high prevalence of the disorder and the availability of treatment options in the region, especially in the developed markets such as the US and Canada.
In 2018, the global Epilepsy Drugs market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.
This report focuses on the global Epilepsy Drugs status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Epilepsy Drugs development in United States, Europe and China.
The key players covered in this study
Abbott Laboratories
GlaxoSmithKline Plc
UCB
Cephalon
Johnson & Johnson
Pfizer
Novartis AG
Abbvie
Janssen Pharmaceuticals
Sunovion Pharmaceuticals
Valeant Pharmaceuticals International
Sanofi S.A
Shire
Eisai
F. Hoffmann-La Roche
Market segment by Type, the product can be split into
First Generation
Second Generation
Market segment by Application, split into
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America
The study objectives of this report are:
To analyze global Epilepsy Drugs status, future forecast, growth opportunity, key market and key players.
To present the Epilepsy Drugs development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of Epilepsy Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Report Overview
- 1.1 Study Scope
- 1.2 Key Market Segments
- 1.3 Players Covered
- 1.4 Market Analysis by Type
- 1.4.1 Global Epilepsy Drugs Market Size Growth Rate by Type (2014-2025)
- 1.4.2 First Generation
- 1.4.3 Second Generation
- 1.5 Market by Application
- 1.5.1 Global Epilepsy Drugs Market Share by Application (2014-2025)
- 1.5.2 Hospital Pharmacies
- 1.5.3 Retail Pharmacies
- 1.5.4 Online Pharmacies
- 1.6 Study Objectives
- 1.7 Years Considered
2 Global Growth Trends
- 2.1 Epilepsy Drugs Market Size
- 2.2 Epilepsy Drugs Growth Trends by Regions
- 2.2.1 Epilepsy Drugs Market Size by Regions (2014-2025)
- 2.2.2 Epilepsy Drugs Market Share by Regions (2014-2019)
- 2.3 Industry Trends
- 2.3.1 Market Top Trends
- 2.3.2 Market Drivers
- 2.3.3 Market Opportunities
3 Market Share by Key Players
- 3.1 Epilepsy Drugs Market Size by Manufacturers
- 3.1.1 Global Epilepsy Drugs Revenue by Manufacturers (2014-2019)
- 3.1.2 Global Epilepsy Drugs Revenue Market Share by Manufacturers (2014-2019)
- 3.1.3 Global Epilepsy Drugs Market Concentration Ratio (CR5 and HHI)
- 3.2 Epilepsy Drugs Key Players Head office and Area Served
- 3.3 Key Players Epilepsy Drugs Product/Solution/Service
- 3.4 Date of Enter into Epilepsy Drugs Market
- 3.5 Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type and Application
- 4.1 Global Epilepsy Drugs Market Size by Type (2014-2019)
- 4.2 Global Epilepsy Drugs Market Size by Application (2014-2019)
5 United States
- 5.1 United States Epilepsy Drugs Market Size (2014-2019)
- 5.2 Epilepsy Drugs Key Players in United States
- 5.3 United States Epilepsy Drugs Market Size by Type
- 5.4 United States Epilepsy Drugs Market Size by Application
6 Europe
- 6.1 Europe Epilepsy Drugs Market Size (2014-2019)
- 6.2 Epilepsy Drugs Key Players in Europe
- 6.3 Europe Epilepsy Drugs Market Size by Type
- 6.4 Europe Epilepsy Drugs Market Size by Application
7 China
- 7.1 China Epilepsy Drugs Market Size (2014-2019)
- 7.2 Epilepsy Drugs Key Players in China
- 7.3 China Epilepsy Drugs Market Size by Type
- 7.4 China Epilepsy Drugs Market Size by Application
8 Japan
- 8.1 Japan Epilepsy Drugs Market Size (2014-2019)
- 8.2 Epilepsy Drugs Key Players in Japan
- 8.3 Japan Epilepsy Drugs Market Size by Type
- 8.4 Japan Epilepsy Drugs Market Size by Application
9 Southeast Asia
- 9.1 Southeast Asia Epilepsy Drugs Market Size (2014-2019)
- 9.2 Epilepsy Drugs Key Players in Southeast Asia
- 9.3 Southeast Asia Epilepsy Drugs Market Size by Type
- 9.4 Southeast Asia Epilepsy Drugs Market Size by Application
10 India
- 10.1 India Epilepsy Drugs Market Size (2014-2019)
- 10.2 Epilepsy Drugs Key Players in India
- 10.3 India Epilepsy Drugs Market Size by Type
- 10.4 India Epilepsy Drugs Market Size by Application
11 Central & South America
- 11.1 Central & South America Epilepsy Drugs Market Size (2014-2019)
- 11.2 Epilepsy Drugs Key Players in Central & South America
- 11.3 Central & South America Epilepsy Drugs Market Size by Type
- 11.4 Central & South America Epilepsy Drugs Market Size by Application
12 International Players Profiles
- 12.1 Abbott Laboratories
- 12.1.1 Abbott Laboratories Company Details
- 12.1.2 Company Description and Business Overview
- 12.1.3 Epilepsy Drugs Introduction
- 12.1.4 Abbott Laboratories Revenue in Epilepsy Drugs Business (2014-2019)
- 12.1.5 Abbott Laboratories Recent Development
- 12.2 GlaxoSmithKline Plc
- 12.2.1 GlaxoSmithKline Plc Company Details
- 12.2.2 Company Description and Business Overview
- 12.2.3 Epilepsy Drugs Introduction
- 12.2.4 GlaxoSmithKline Plc Revenue in Epilepsy Drugs Business (2014-2019)
- 12.2.5 GlaxoSmithKline Plc Recent Development
- 12.3 UCB
- 12.3.1 UCB Company Details
- 12.3.2 Company Description and Business Overview
- 12.3.3 Epilepsy Drugs Introduction
- 12.3.4 UCB Revenue in Epilepsy Drugs Business (2014-2019)
- 12.3.5 UCB Recent Development
- 12.4 Cephalon
- 12.4.1 Cephalon Company Details
- 12.4.2 Company Description and Business Overview
- 12.4.3 Epilepsy Drugs Introduction
- 12.4.4 Cephalon Revenue in Epilepsy Drugs Business (2014-2019)
- 12.4.5 Cephalon Recent Development
- 12.5 Johnson & Johnson
- 12.5.1 Johnson & Johnson Company Details
- 12.5.2 Company Description and Business Overview
- 12.5.3 Epilepsy Drugs Introduction
- 12.5.4 Johnson & Johnson Revenue in Epilepsy Drugs Business (2014-2019)
- 12.5.5 Johnson & Johnson Recent Development
- 12.6 Pfizer
- 12.6.1 Pfizer Company Details
- 12.6.2 Company Description and Business Overview
- 12.6.3 Epilepsy Drugs Introduction
- 12.6.4 Pfizer Revenue in Epilepsy Drugs Business (2014-2019)
- 12.6.5 Pfizer Recent Development
- 12.7 Novartis AG
- 12.7.1 Novartis AG Company Details
- 12.7.2 Company Description and Business Overview
- 12.7.3 Epilepsy Drugs Introduction
- 12.7.4 Novartis AG Revenue in Epilepsy Drugs Business (2014-2019)
- 12.7.5 Novartis AG Recent Development
- 12.8 Abbvie
- 12.8.1 Abbvie Company Details
- 12.8.2 Company Description and Business Overview
- 12.8.3 Epilepsy Drugs Introduction
- 12.8.4 Abbvie Revenue in Epilepsy Drugs Business (2014-2019)
- 12.8.5 Abbvie Recent Development
- 12.9 Janssen Pharmaceuticals
- 12.9.1 Janssen Pharmaceuticals Company Details
- 12.9.2 Company Description and Business Overview
- 12.9.3 Epilepsy Drugs Introduction
- 12.9.4 Janssen Pharmaceuticals Revenue in Epilepsy Drugs Business (2014-2019)
- 12.9.5 Janssen Pharmaceuticals Recent Development
- 12.10 Sunovion Pharmaceuticals
- 12.10.1 Sunovion Pharmaceuticals Company Details
- 12.10.2 Company Description and Business Overview
- 12.10.3 Epilepsy Drugs Introduction
- 12.10.4 Sunovion Pharmaceuticals Revenue in Epilepsy Drugs Business (2014-2019)
- 12.10.5 Sunovion Pharmaceuticals Recent Development
- 12.11 Valeant Pharmaceuticals International
- 12.12 Sanofi S.A
- 12.13 Shire
- 12.14 Eisai
- 12.15 F. Hoffmann-La Roche
13 Market Forecast 2019-2025
- 13.1 Market Size Forecast by Regions
- 13.2 United States
- 13.3 Europe
- 13.4 China
- 13.5 Japan
- 13.6 Southeast Asia
- 13.7 India
- 13.8 Central & South America
- 13.9 Market Size Forecast by Product (2019-2025)
- 13.10 Market Size Forecast by Application (2019-2025)
14 Analyst's Viewpoints/Conclusions
15 Appendix
- 15.1 Research Methodology
- 15.1.1 Methodology/Research Approach
- 15.1.1.1 Research Programs/Design
- 15.1.1.2 Market Size Estimation
- 12.1.1.3 Market Breakdown and Data Triangulation
- 15.1.2 Data Source
- 15.1.2.1 Secondary Sources
- 15.1.2.2 Primary Sources
- 15.1.1 Methodology/Research Approach
- 15.2 Disclaimer
Summary:
Get latest Market Research Reports on Epilepsy Drugs . Industry analysis & Market Report on Epilepsy Drugs is a syndicated market report, published as Global Epilepsy Drugs Market Size, Status and Forecast 2019-2025. It is complete Research Study and Industry Analysis of Epilepsy Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
